Disclaimer

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at [www.sec.gov](http://www.sec.gov).
Highlights

- U.S. based company - NASDAQ traded
- Launching first product in China in fiscal 2019
- Strong cash runway, with expected revenue in 2019
- Backed by returning committed investors and new investors
- Experienced management team with deep knowledge of tech transfer & commercialization in both the Chinese & U.S. markets
- Initial products address and estimated $3 billion market opportunity in China & $700 million in U.S.
- Expected to rapidly penetrate Chinese market as centralized structure of patient care results in less fragmented delivery system
- Upside in U.S. generics market once fully integrated
- Active BD for additional products to take advantage of scalable platform
Building a Global U.S. and China Driven Pharmaceutical Company as Platform to Accelerate Medicine Launch

- NASDAQ company with seamless cross-border operations in Maryland, Beijing, and GMP manufacturing facility in Wuxi, China scheduled for construction in 2019
- Over 90 employees in U.S. and China, global operations led by senior executive team in the U.S.
- Management team with extensive network and expertise in U.S./China regulatory to maximize synergies and current reforms in China
- First drug launch in China fiscal 2019
  - (Melphalan Hydrochloride, marketed in the U.S. as EVOMELA® for multiple myeloma), transitioning CASI into a commercial enterprise
- Diverse pipeline of in-licensed drugs in hematology & HBV for China, ANDAs for multiple indications, and proprietary oncology drugs in development
  - Provide our patients and partners with a full range of solutions to effectively combat diseases and improve quality of life
- Focused on acquiring and licensing late-stage or approved products
Management Team

Wei-Wu He, Ph.D.
Executive Chairman

Ken Ren, Ph.D.
Chief Executive Officer & Director

George Chi, CPA, CFA
Chief Financial Officer

Alexander A. Zukiwski, M.D.
Chief Medical Officer

Cynthia W. Hu
COO, General Counsel & Secretary

James E. Goldschmidt
Senior Vice President, Business Development

Larry Zhang
President, CASI China

Cissy Wang
Chief Operating Officer, CASI China

Thomas Zhang
General Manager, Sales & Marketing, CASI China

Allan Hong
General Manager, Wuxi Manufacturing Facility, CASI China

Michael Wu
Head of Regulatory, CASI China

Yolanda Zhang
Head of Clinical, CASI China
Board of Directors

WEI-WU HE, PH.D.
Executive Chairman

QUAN ZHOU, PH.D.
Compensation Committee

JAMES HUANG
Audit Committee

RAJESH SHROTRIYA, M.D.

ALEXANDER WU, PH.D.
Audit & Compensation Committees

FRANKLIN SALISBURY, JR.
Audit & Compensation Committees

IDG-ACCEL China Fund Venture Partner; Managing Director of ETP Global Fund, L.P.; Chairman & CEO, OriGene Technologies, Inc.

Founder, Managing Director & General Partner at IDG Capital Partners

General Partner, Kleiner Perkins Caufield & Byers China, Launched Panacea Venture in 2017

Spectrum Pharmaceuticals, Inc., Chairman & CEO, 2000-2017


President, National Foundation for Cancer Research
Mission: Bring Innovative Medicines and Specialty Pharmaceuticals to 1.4 Billion People in Greater China while Addressing the U.S. and Global Markets Efficiently

- CASI is uniquely positioned to capitalize on recent NMPA reforms to bring innovative products & ANDAs into the China market
  - Recent National Medical Products Administration* (NMPA) (China FDA) reforms ensure quality and allow for expedited approval of NDAs and ANDAs for innovative products
  - Accelerate development, registration and commercialization of products for both the China and U.S./Global markets
    » Large population in China for rapid patient recruitment to reach value inflection points quickly and cost-effectively
    » High quality, low cost manufacturing by FDA-approved GMP facilities in China can be leveraged on a worldwide basis
- Expected to rapidly penetrate Chinese market as centralized structure of patient care results in less fragmented delivery system relative to other countries
- Transition manufacturing of U.S. ANDAs to China ensuring fast track review
  - Manufacture at reduced costs for both China and U.S. markets

*The National Medical Products Administration (NMPA) is the Chinese agency for regulating drugs and medical devices (formerly the China Food and Drug Administration or CFDA)
Building Value by Focusing on Pharmaceutical Growth Segments – Hepatitis & Hematology

Building growth segments in China to provide a range of treatment options to patients

**Hepatitis segment**

- **Entecavir (ETV)**
  - Antiviral medication used in the treatment of hepatitis B virus (HBV) infection
  - Based on prior generic sales, CASI estimates sales of ETV for 2016 in China would have been $1.5 billion
- **Tenofovir disoproxil fumarate (TDF)**
  - Nucleotide analog reverse transcriptase inhibitor indicated for the treatment of chronic HBV
- Entecavir and TDF will benefit ~ 40M patients in China
- In active pursuit to acquire and market other products for HBV, NASH and other liver diseases

**Hematology segment**

- **EVOMELA®** (Melphalan Hydrochloride for Injection): preparing for 2019 launch
- **ZEVALIN®**: NMPA CTA review in progress
- **MARQibo®**: NMPA CTA review in progress

*According to U.S. Health and Human Services (HHS), in the United States, an estimated 850,000 - 2.2 million persons are chronically infected with the hepatitis B virus. Globally, HBV is the most common blood-borne infection with an estimated 240 million people chronically infected according to the World Health Organization*
Diversified Product Portfolio

**Acquired From SPPI**
- Evomela (melphalan for Injection)
- ZEVALIN (ibritumomab tiuxetan)
- Marqibo (vinCRIStine sulfate LIPOSOME injection)

**Acquired From Sandoz:**
- 25 FDA Approved ANDAs
- 4 FDA Pending ANDAs

**Acquired TDF from Laurus Labs:**
- ANDA for tenofovir disoproxil fumarate (TDF)

**Greater China Rights**

**U.S. FDA ANDAs**

**Global rights**

**ENMD-2076**
Innovative Drug Candidate
Targeted Therapy for Solid Tumors

Diverse Portfolio Across Attractive Therapeutic Area

- 35%
- 8%
- 11%
- 15%
- 19%
- 12%

- Hypertension/PVD
- Metabolic Disorders
- Anti-infectious
- Others

ENMD-2076 (Aurora A)
(VEGFR, FGFR)

Angiogenic Kinases

Growth Factor Kinases
(Kit-3, c-Kit, CSF1R)
Diversified Product Portfolio - Innovative Medicines

Greater China regional licenses from Spectrum; CASI responsible for development and commercialization in China, including Taiwan, Hong Kong, and Macau

- Import drug registration applications
- Confirmatory clinical studies
- Premarketing and commercial launches

EVOMELA® (Melphalan Hydrochloride for Injection): China Marketing Approval December 2018 under new priority review guidelines – 2019 Launch

- **Indication**: use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma, and the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate

ZEVALIN®: NMPA CTA review in progress

- **Indication**: treatment of non-Hodgkin’s Lymphoma

MARQibo®: NMPA CTA review in progress

- **Indication**: treatment of acute lymphoblastic leukemia

- Development & Commercialization Partnership with Spectrum Pharmaceuticals
- NMPA is the Chinese agency for regulating drugs and medical devices (formerly the China Food & Drug Administration (CFDA))
### Key Products from ANDA Pipeline Based on 2016 (Estimated) Generic Sales in China

<table>
<thead>
<tr>
<th>Product</th>
<th>Indication</th>
<th>2016E Sales (in US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Entecavir tablet</td>
<td>Chronic HBV Infection</td>
<td>1,490,000,000</td>
</tr>
<tr>
<td>Bisoprolol Fumarate tablet</td>
<td>Hypertension</td>
<td>205,000,000</td>
</tr>
<tr>
<td>Desvenlafaxine SR tablet</td>
<td>Depression</td>
<td>170,000,000</td>
</tr>
<tr>
<td>Aripiprazole tablet</td>
<td>Schizophrenia</td>
<td>108,000,000</td>
</tr>
<tr>
<td>Cilostazol tablet</td>
<td>Peripheral vascular disease</td>
<td>65,000,000</td>
</tr>
<tr>
<td><strong>Total Estimated Sales</strong></td>
<td><strong>Total Estimated Sales</strong></td>
<td><strong>US $2,038,000,000</strong></td>
</tr>
</tbody>
</table>

* Source: China’s PDB Database
GMP Manufacturing Facility in Wuxi, China – Construction in 2019

• Building state-of-the-art GMP manufacturing facility strategically located in the Wuxi Huishan Economic Development Zone in Jiangsu Province, China
  – Currently in design phase, set to break ground on Phase 1 mid/late 2019
  – CASI can maintain an efficient Chinese sales force by focusing on 100 Tier 1 hospitals

• Backing from Wuxi government

• Centrally located with convenience of mass transportation (direct train from the airport)

• Large scale production: yearly output capacity of >4 billion tablets with maximum capacity of 12 billion tablets

• In-house manufacturing facility will allow greater controls over quality and cost of goods
Recap

- U.S. based company - NASDAQ traded
- Launching first product in China during 2019
- Strong cash runway, with expected revenue in 2019
- Backed by returning committed investors and new investors
- Experienced cross-border management team with deep knowledge of tech transfer & commercialization in both the Chinese & U.S. markets
- Initial products address and estimated $3 billion market opportunity in China & $700 million in U.S.
- Expected to rapidly penetrate Chinese market as centralized structure of patient care results in less fragmented delivery system
- Upside in U.S. generics market once fully integrated
- Active BD to take advantage of scalable platform
Thank you